Coming soon
-
Coming soon -
WELCOME
Building on Success: Advancing Medication Safety Together
We are thrilled to announce Iraq’s continued participation in the global MedSafetyWeek 2025 campaign, proudly represented by the Iraqi Pharmacovigilance Center at the Directorate of Technical Affairs, Ministry of Health. Building on the outstanding success of last year’s campaign, we are delighted to announce our event once again, continuing our shared mission.
This year’s campaign marks the 10th global edition of MedSafetyWeek, and we are honored to stand alongside all pharmacovigilance stakeholders in the public and the private sector, reinforcing the critical importance of medication safety. Building on last year’s focus on preventing adverse drug reactions and reducing medication errors, MedSafetyWeek 2025 shifts attention to strengthening national pharmacovigilance systems and promoting the implementation and effectiveness of risk minimization measures.
Everyone has a role to play. Together, we can strengthen pharmacovigilance in Iraq and around the world, ensuring that every patient receives safe and effective care. Let’s continue to report, learn, and improve—because medication safety begins with each of us.
Welcome to MedSafetyWeek 2025 uniting for safer healthcare!
TOPICS AND OBJECTIVES
3. Networking Opportunities
MedSafetyWeek provides an excellent platform for professionals to connect and exchange insights. We encourage all participants to actively engage in discussions and share their expertise to foster collective learning.
1. Pharmacovigilance System
We will explore the structure and functioning of pharmacovigilance systems in Iraq, with a focus on roles across regulators, healthcare institutions, and marketing authorization holders (MAHs). Topics will include regulatory requirements, the organization and maintenance of the Pharmacovigilance System Master File, data quality standards, coding practices, and the importance of coordinated effo highlight its central role in oversight, system strengthening, and collaboration with all stakeholders.
2. Advancing Risk Minimization Measures (RMMs)
A great focus will be placed on the end-to-end process of risk minimization—from design to real-world effectiveness. It will explore the role of MAHs in developing additional RMMs such as educational materials, prescriber guides, and restricted distribution programs, ensuring they are appropriate for the local context. The discussion will also cover regulatory expectations for designing RMMs based on specific safety concerns, adapting them to the local healthcare setting, engaging healthcare professionals and patient, and evaluating the effectiveness with measurable outcomes.
